LBA02-07 HERO PHASE 3 TRIAL: RESULTS COMPARING RELUGOLIX, AN ORAL GNRH RECEPTOR ANTAGONIST, VS LEUPROLIDE ACETATE FOR ADVANCED PROSTATE CANCER
| Autor: | Bryan Selby, Vicky Kang, Michael S. Cookson, Ronald Tutrone, Daniel Saltzstein, Jackie Walling, Xiaolin Fan, Hideyuki Akaza, David van Veenhuyzen, Alberto Bossi, Neal D. Shore, Bertrand Tombal, David J. George, Fred Saad |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
musculoskeletal diseases
endocrine system medicine.medical_specialty Gnrh receptor business.industry Urology Delayed onset Antagonist medicine.disease chemistry.chemical_compound Prostate cancer Endocrinology Castration chemistry Internal medicine medicine business hormones hormone substitutes and hormone antagonists Testosterone |
| Zdroj: | Journal of Urology. 203 |
| ISSN: | 1527-3792 0022-5347 |
| DOI: | 10.1097/ju.0000000000000958.07 |
| Popis: | Introduction:LHRH agonists are the mainstay for medical castration in advanced prostate cancer, however, they cause an initial testosterone (T) surge with a delayed onset of castration and require ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|